Apidra OptiSet Injection 100 IU 5 Pre filled Syringex3 mL

Frequently asked questions

• Onset of action

  The effect of this medicine can be observed within 15-30 minutes of administration of the dose.

• Duration of Effect

  The effect of this medicine lasts for an average duration of 5 hours.

• Safe with Alchohol?

  Consumption of alcohol is not recommended during treatment with this medicine due to the increased risk of both hypoglycemia (low blood glucose levels) and hyperglycemia (high blood glucose levels) depending on the quantity and frequency of alcohol consumption. This may cause severe side effects such as dizziness, drowsiness, increased thirst, increased hunger, mood changes, extreme fatigue, etc.

• Is it habit forming?

  No habit-forming tendencies were reported.

• Usage in pregnancy?

  This medicine is considered safe for use by pregnant women. However, it must be used only when necessary and the potential benefits outweigh the risks.

• Usage while breast-feeding?

  Use of insulin by breastfeeding women is considered acceptable. Breastfeeding women generally require lower doses of insulin.

• Allergy

  This medicine is not recommended for use in patients with a known allergy to Apidra OptiSet Injection 100 IU 5 Pre filled Syringex3 mL or any other inactive ingredients present along with it.

• Hypoglycemia

  This medicine is not recommended for use in patients suffering from decreased blood sugar levels (hypoglycemia) since it may worsen the patient's condition.

• Pregnancy

  This medicine is considered safe for use by pregnant women. However, it must be used only when necessary and the potential benefits outweigh the risks.

• Breast-feeding

  Use of insulin by breastfeeding women is considered acceptable. Breastfeeding women generally require lower doses of insulin.

• Hypersensitivity reactions

  This medicine may cause serious and occasionally fatal hypersensitivity reactions (severe allergic reactions) including anaphylactic shock in some patients. Seek immediate medical intervention if any signs and symptoms of an allergic reaction such as skin rash, sore throat, difficulty breathing, swelling of the face, etc. occur. If an anaphylactic reaction occurs, the treatment should be discontinued immediately and appropriate corrective measures should be undertaken.

• Hypoglycemia

  This medicine may cause hypoglycemia (low blood glucose levels) in some patients. This risk is especially higher in patients suffering from kidney diseases, malnourishment, pituitary gland diseases, etc. Close monitoring of blood glucose levels is recommended for such patients. Appropriate dose adjustments may be required based on the clinical condition. Your doctor may advise you to carry a sugar candy to counteract the effects of low blood sugar levels (hypoglycemia).

• Hypokalemia (Decreased potassium levels)

  This medicine should be used with caution in patients at risk of developing hypokalemia or patients suffering from hypokalemia since it may worsen the patient's condition. Close monitoring of potassium levels, appropriate corrective measures, or dose adjustments may be required based on the clinical condition.

• Driving and Operating machinery

  This medicine may cause symptoms such as weakness, drowsiness, sleepiness, dizziness, inability to concentrate etc. in some patients. It is advised that you do not perform any activities such as driving a vehicle or operating heavy machinery if you experience any of these symptoms during treatment with this medicine.

• Heart Failure

  This medicine should be used with extreme caution in patients who are concomitantly taking PPAR-gamma agonists (Thiazolidinediones) due to the increased risk of fluid retention which may exacerbate to heart failure. Frequent clinical monitoring is advised in such patients. Report any unusual symptoms to the doctor on priority. Do not stop the use of any medicine without consulting your doctor.

• Use in Children

  This medicine is not recommended for use in patients below 18 years of age for treating type II diabetes and for that of type 1 diabetes mellitus is 4 years of age since the safety and efficacy of use are not clinically established.

• Single Person Use

  This medicine (pen) should not be shared with others even if the needle is changed. Sharing of syringes or needles with another person, who are using vials is strictly not advised.

• Route of Administration

  In specific circumstances, some formulations of this medicine can also be administered intravenously in infusion systems using polypropylene infusion bags strictly under the medical supervision of a qualified healthcare professional.

Carefully follow all the instructions given by your doctor. Do not administer in larger or smaller amounts than advised/prescribed. Consult the doctor if you experience any undesirable side effects. Do not stop the use of this medicine without consulting your doctor. Close monitoring of blood glucose levels and frequent follow-up visits with the doctor may be required based on the clinical condition. Never share an injection pen, cartridge, or syringe with another person, even if the needle has been changed.

• To be taken before food
• To be taken as instructed by doctor
• May cause sleepiness

• medlineplus.gov - Insulin Glulisine [Internet]. Available from: https://medlineplus.gov/druginfo/meds/a607033.html [cited 7/8/2020]. 2020